← Back to Clinical Trials
Recruiting NCT06764459
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
Trial Parameters
Condition Myeloid Leukemia, Acute
Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study Type OBSERVATIONAL
Phase N/A
Enrollment 20
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-03-15
Completion 2025-12-31
Brief Summary
This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their evolution during therapeutic treatment.
Eligibility Criteria
Inclusion Criteria: * FLT3 mutated Exclusion Criteria: * Respoder to therapy